期刊文献+

Portal thrombosis and steatosis after preoperative chemotherapy with FOLFIRI-bevacizumab for colorectal liver metastases 被引量:2

Portal thrombosis and steatosis after preoperative chemotherapy with FOLFIRI-bevacizumab for colorectal liver metastases
下载PDF
导出
摘要 In order to discuss the role of preoperative chemo- therapy for colorectal liver metastases, which is used frequently before hepatic resection, even in patients with resectable disease at presentation, we herein report the development of two complications, partial portal vein thrombosis and hepatic steatosis with Iobular inflammation, during the course of preoperative chemotherapy with FOLFIRI plus bevacizumab for colorectal liver metastases, which recognition led to timely discontinuation of chemotherapy as well as a change in the surgical strategy to resect the tumors and the damaged liver through advanced techniques. We conclude that duration of treatment and drug doses and combinations may impact the development of chemotherapy-induced liver injury. Surgeons and medical oncologists must work together to devise safe, rational, and oncologically appropriate treatments for patients with multiple colorectal liver metastases, and to improve the understanding of the pathogenesis of chemotherapyinduced liver injury. In order to discuss the role of preoperative chemo-therapy for colorectal liver metastases, which is used frequently before hepatic resection, even in patients with resectable disease at presentation, we herein report the development of two complications, partial portal vein thrombosis and hepatic steatosis with lobular inflammation, during the course of preoperative chemotherapy with FOLFIRI plus bevacizumab for colorectal liver metastases, which recognition led to timely discontinuation of chemotherapy as well as a change in the surgical strategy to resect the tumors and the damaged liver through advanced techniques. We conclude that duration of treatment and drug doses and combinations may impact the development of chemotherapy-induced liver injury. Surgeons and medical oncologists must work together to devise safe, rational, and oncologically appropriate treatments for patients with multiple colorectal liver metastases, and to improve the understanding of the pathogenesis of chemotherapy-induced liver injury.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2006年第40期6556-6558,共3页 世界胃肠病学杂志(英文版)
关键词 CHEMOTHERAPY Colorectal liver metastases RESECTION 血栓形成 化学疗法 病理 治疗 临床
  • 相关文献

参考文献18

  • 1[1]Choti MA,Sitzmann JV,Tiburi MF,Sumetchotimetha W,Rangsin R,Schulick RD,Lillemoe KD,Yeo CJ,Cameron JL.Trends in long-term survival following liver resection for hepatic colorectal metastases.Ann Surg 2002;235:759-766
  • 2[2]Abdalla EK,Vauthey JN,Ellis LM,Ellis V,Pollock R,Broglio KR,Hess K,Curley SA.Recurrence and outcomes following hepatic resection,radiofrequency ablation,and combined resection/ablation for colorectal liver metastases.Ann Surg 2004;239:818-825;discussion 825-827
  • 3[3]Pawlik TM,Scoggins CR,Zorzi D,Abdalla EK,Andres A,Eng C,Curley SA,Loyer EM,Muratore A,Mentha G,Capussotti L,Vauthey JN.Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases.Ann Surg 2005;241:715-722,discussion 722-724
  • 4[4]Gordon MS,Cunningham D.Managing patients treated with bevacizumab combination therapy.Oncology 2005;69 Suppl 3:25-33
  • 5[5]Shah MA,Ilson D,Kelsen DP.Thromboembolic events in gastric cancer:high incidence in patients receiving irinotecanand bevacizumab-based therapy.J Clin Oncol 2005;23:2574-2576
  • 6[6]Ellis LM,Curley SA,Grothey A.Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab.J Clin Oncol 2005;23:4853-4855
  • 7[7]Scappaticci FA,Fehrenbacher L,Cartwright T,Hainsworth JD,Heim W,Berlin J,Kabbinavar F,Novotny W,Sarkar S,Hurwitz H.Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.J Surg Oncol 2005;91:173-180
  • 8[8]Skillings JR,Johnson DH,Miller K,Kabbinavar E,Bergsland E,Holmgren SN Holden SN,Hurwitz H,Scappaticci F.Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized,controlled trials (RCTs) of bevacizumab (BV)with chemotherapy.Proc Am Soc Clin Oncol 2005;3019
  • 9[9]Kilickap S,Abali H,Celik I.Bevacizumab,bleeding,thrombosis,and warfarin.J Clin Oncol 2003;21:3542
  • 10[10]Zakarija A,Soff G.Update on angiogenesis inhibitors.Curr Opin Oncol 2005;17:578-583

同被引文献6

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部